An Open-label, Single-dose, 3-Period Crossover Study to Evaluate the 2-way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects

Withdrawn

• Conditions: Diabetes; Hypertension; Metabolic and Endocrine - Diabetes; Cardiovascular - Hypertension

• Registration Number: ACTRN12612000582853
• Lead Sponsor: Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Subject judged to be in good health based on medical history, physical examination, ECG, vital sign measurements and laboratory safety tests
-Non-smoker
-BMI <30kg/m2

Exclusion Criteria

-Mentally or legally incapacitated or having significant emotional problems or has a history of clinically significant psychiatric disorder
-History of any clinically significant diseases/disorders, myopathic disorder or history of rhabdomyolysis.
-Creatinine clearance <80mL/min
-History of neoplastic disease
-Pregnant, breast feeding or expecting to conceive
-Major surgery or blood donation within 4 weeks
-Consumes excessive amounts of alcohol or caffeine
-History of significant allergies, anaphylactic reaction or significant intolerance to prescription/non-prescription drugs or food.
-Regular/recreational drug user
-History of hypersensitivity to sitagliptin, losartan or any of the tablet excipients

Study & Design

• Study Type: Interventional
• Study Design: Not specified